Baird lowered the firm’s price target on Iqvia (IQV) to $223 from $256 and keeps a Neutral rating on the shares. The firm said they are concerned about CRO marketplace dynamics near term and with 60% of the company reporting slow or weakening trend, they question whether the 40% that is improving will do much more than provide balance.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks